Categories
- About MIMS Ireland
- New Products
- New Presentations
- New this Month
- Discontinued Products
- New Clinical Evidence
- Clinical Specials
- Irish Medicines Board
- Medicines and Sport
Archives
- December 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- November 2007
- October 2007
Tagcloud
ACE inhibitor, acetylcholinesterase inhibitor, aciclovir, acne, acute coronary syndrome, acute lymphoblastic leukaemia, ADHD, advanced prostate cancer, advanced renal cell carcinoma, advanced soft tissue sarcoma, adverse reaction, agomelatine, agoraphobia, alendronic acid, alfuzosin, algorithm, aliskiren, allergic rhinitis, allopurinol, alpha1-proteinase inhibitor, Alzheimer's, amantadine hydrochloride, ambrisentan, aminosalicylate, amlodipine, amoxicillin, anaemia, angina pectoris, anidulafungin, ankylosing spondylitis, anti-doping, anti-heparin, anti-human thymocyte immunoglobulin, antibacterial, antibiotic, anticoagulant, antidepressant, antineoplastic, antipsychotic, antiretroviral, antiretroviral therapy, anxiety, aromatase inhibitor, asthma, atazanavir, azacitidine, bacterial infections, BCG Vaccine, beclometasone, behaviour disorders, betamethasone, bevacizumab, bicalutamide, bipolar disorder, bisoprolol fumarate, bisphosphonates, black patients, bladder cancer, bowel cleansing, BPH, breakthrough pain, breast cancer, brinzolamide, bronchospasm, budesonide, bulimia nervosa, calcipotriol, calcium, candesartan, Candida albicans, candidiasis, carbetocin, carbidopa, cardiac insufficiency, cardiovascular disease, cefaclor, ceftriaxone, cefuroxime, cephalosporin, cetirizine, CHF, cholecalciferol, chronic constipation, chronic heart failure, Chronic Kidney Disease, chronic myeloid leukaemia, chronic myelomonocytic leukaemia, chronic pain, chronic pulmonary infection, ciprofloxacin, citalopram hydrobromide, clarithromycin, clavulanic acid, clopidogrel, clotrimazole, clozapine, colorectal cancer, contraception, COPD, coronary artery disease, Crohn’s Disease, cystic fibrosis, dabigatran etexilate, daptomycin, darunavir, dasatinib, degarelix, dementia, depression, dermatophytes, dermatophytose, desogestrel, diabetes, diclofenac, dienogest, diphteria, discontinuations, domperidone, donepezil, doxazosin, doxycycline, drospirenone, duodenal ulcer, dyslipidaemia, eczema, eletriptan, emetogenic cancer chemotherapy, enalapril, endocarditis, entacapone, epigastric bloating, epilepsy, epirubicin, epoetin, ErbB2 (HR2) receptors, erythropoiesis-stimulating agents, esomeprazole, estradiol, ethinylestradiol, etravirine, everolimus, exemestane, faecal impaction, famciclovir, fentanyl, fesoterodine, fever, filgrastim, finasteride, fluconazole, fluoxetine, flurbiprofen, fluvastatin, folate, folic acid, follicular development stimulation, follicular lymphoma, follitropin alpha, fosprepitant, fungal infections, gabapentin, gastric cancer, gastric ulcer, gastroduodenal ulcer, gemcitabine, gestodene, gliclazide, glucosamine sulphate, gonorrhoea, GORD, growth failure, H1N1, hayfever, heart failure, heart rate, Helicobacter pylori, hepatic failure, hepatitis, hepatocellular carcinoma, herpes, hip or knee replacement surgery, hip osteoarthritis, HIV, hyaluronic acid, hydrochlorothiazide, Hylan G-F 20, hypercholesterolaemia, hyperlipidaemia, hyperphosphataemia, hypertension, hyperuricaemia, hypoactive sexual desire disorder, ibritumomab, ibuprofen, IGF-1 deficiency, IMB, immunosuppression, indacaterol, indapamide, infections, inflammation, influenza, insomnia, interferon beta-1a, iobetasol, IOP, ipatropium bromide, irinotecan, Irish Sports Council, ischaemic stroke, isotretinoin, ivabradine, Kaposi's sarcoma, kidney cancer, kidney disease, knee osteoarthritis, lacosamide, lamotrigine, lansoprazole, lapatinib, laropiprant, lenalidomide, lercanidipine, leuprorelin acetate, levodopa, levonorgestrel, liraglutide, lisinopril, losartan, lutropin alpha, Lyme disease, macrogol, magnesium, mania, maraviroc, mecasermin, melatonergic, melatonin, meloxicam, memantine, mesalazine, metastatic colorectal carcinoma, metformin, methadone, methylnaltrexone bromide, methylphenidate hydrochloride, mexiletine hydrochloride, micafungin, migraine, mirtazapine, mixed dyslipidaemia, moxifloxacin, multiple myeloma, multiple sclerosis, muscular disorders, myelodysplastic syndromes, myocardial infarction, naloxone, naratriptan, nasal congestion, nausea, nebivolol, nephropathy, neural tube defects, neutropenia, NICE guidelines, nicotine, nicotinic acid, nilotinib, NSCLC, nutrition, OCD, ocular hypertension, olanzapine, olmesartan, omeprazole, ondensetron, open angle glaucoma, opioid addiction, opioid analgesic, opioid-induced constipation, oseltamivir, osteoarthritis, osteonecrosis of the jaw, osteoporosis, otitis, ovarian cancer, overactive bladder syndrome, oxycodone, paclitaxel, pain, pancreatic cancer, pancreatic exocrine insufficiency, pancreatin, panic disorder, panitumumab, pantoprazole, paracetamol, Parkinson’s, partial-onset seizures, patch, pemetrexed, peptic ulcer, perindopril, peripheral arterial disease, peripheral neuropathic pain, pertussis, piperacillin, Pityriasis versicolor, poliomyelitis, post transplantation hyperlipidaemia, post-operative pain, post-traumatic stress disorder, PPIs, pramipexole, pravastatin, pregnancy, pricing policy, primary hypercholesterolaemia, probiotics, prostate cancer, protamine sulphate, Pseudomonas aeruginosa, psoriasis, psychotic disorders, pulmonary arterial hypertension, pulmonary embolism, quetiapine, raltegravir, ramipril, ranolazine, rasagiline, recombinant IGF-1, reflux oesophagitis, renal disease, renin inhibitor, Restless Legs Syndrome, rheumatoid arthritis, ribavirin, ringworm, risedronate sodium, risperidone, rivaroxaban, rivastigmine, romiplostim, ropinirole, rosacea, RTI, S. aureus, salbutamol, sarcoma, saxagliptin, schizophrenia, SCLC, sertraline, sevelamer carbonate, severe pain, simvastatin, sitagliptin, smoking cessation, sodium alginate, solide organ transplantation, sorafenib, sore throat, spasticity, spinal cord injury, sport, sprain, statins, stroke, strontium ranelate, suicide, systemic embolisation, telmisartan, temsirolimus, terbinafine, testosterone, tetanus, thalidomide, thrombocytopenic purpura, thrush, tibolone, timolol, tinea, tiotropium, tipranavir, tizanidine, tobramycin, tocilizumab, topotecan, trabectedin, tramadol, Trichophyton, trimethoprim, trospium chloride, ustekinumab, UTI, vaccine, valaciclovir, valproate, valsartan, varenicline, venlafaxine, venous thromboembolism, venous thrombosis, vildagliptin, vinorelbine, vitamin D, vomiting, WADA, warfarin, wound, zanamivir, zoledronic acid, Zollinger-Ellison syndrome
«Previous article | Next article»
Rispone Oral Solution and Tablets

Company: Rowex Ltd.
Legal category: Prescription. GMS. Sport Permitted.
Active ingredient: Risperidone 1mg/ml oral solution and 0.5mg tablet.
Description: Clear, colourless solution and red oval film-coated tablet with breaking notch.
Presentation: 1mg/ml-100ml, €59.46; 0.5mg-20, €11.26.
Indications: Solution: The treatment of schizophrenia. Maintenance of schizophrenia in responsive patients. Treatment of moderate to severe manic episodes. Solution and 0.5mg tablet: Treatment of severe behavioural disturbances associated with aggressiveness and self-inflicted injury diagnosed according to DSM-IV criteria in children, adolescents and adults with mental retardation.
Dosage: Adult: Schizophrenia: Take once or twice daily. Initially 2mg daily. May increase dose to 4mg on day 2. Usual optimal dose: 4-6mg daily. Doses > 10mg daily did not increase therapeutic effect. Over 16mg, not recommended. Administer as single or divided dose. If sedation required benzodiazepine can be administered concomitantly. Elderly: Initially 0.5mg twice daily. Can be increased with 0.5mg twice daily increments up to 1-2mg twice daily. Manic episodes: Initially 2mg once daily. Adjust dose if indicated at intervals of 24 hours. Recommended dose: 2-6mg daily. Behavioural disturbances: Patients weighing <50kg: Initially 0.25mg once daily; can be increased by an additional 0.25mg once daily no sooner than every second day. Usual maintenance dose, 0.5mg once daily (range 0.25-0.75mg once daily). Patients weighing ≥50kg: Initially 0.5mg once daily; can be increased by an additional 0.5mg once daily no sooner than every second day. Usual maintenance dose, 1mg once daily (range 0. 5-1.5mg once daily). Hepatic/renal impairment: Half starting and maintenance dose as well as slower titration recommended. Children: Schizophrenia: Under 15 years, not recommended. Manic episodes: Under 18 years, not recommended. Behavioural disturbances: Under 5 years, not recommended.
Contraindications: Hypersensitivity to risperidone or to any of the excipients. Pregnancy (unless benefit outweighs risk), lactation. Solution: Preexisting, not drug induced hyperprolactinemia.
Special precautions: Elderly patients with dementia; avoid dehydration in these patients. Dementia patients with history of CVA, TIA, hypertension or diabetes. Can cause orthostatic hypotension. If hypotension occurs consider dose reduction. Long term treatment: Tardive dyskinesia can occur. Neuroleptic malignant syndrome may occur. Caution: Hepatic/renal impairment, elderly, lewy body dementia or Parkinson’s disease, epilepsy , diabetes (or at risk patients), cardiovascular disease (increase gradually due to hypotension risk) or family history of QT prolongation, prolactin-dependent tumours or possible prolactin-dependent tumours,patients exposed to extremes of temperature. Psycho-organicdisturbances, increased risk of undesirable effects. Contains lactose.Driving or using machine.
Drug interactions: Avoid alcohol, other antipsychotics. Caution:Centrally acting drugs, lithium, antidepressants, anti parkinsonian drugs, drugs with a central anticholinergic effect, levodopa and other dopaminergic agonists, carbamazepine or other hepaticenzyme inducing drugs, strong inhibitors of CYP2D6 (e.g. quinidine,fluoxetine, paroxetine, terbinafine), diuretics, antacids, cimetidine, ranitidine, products prolonging QTc interval.
Adverse drug reactions: Insomnia, agitation, anxiety, headache, sedation, weight increase.
Full prescribing information and references available from RowexLtd. Freephone: 1800 304 400. Fax: (027) 50417.E-mail: rowex@rowa-pharma.ie

Posted in 03 New presentations on 01 February 2008
Tags: risperidone, schizophrenia
More articles from IMT MIMS Ireland
